Is the risk of infection higher during treatment with secukinumab than with TNF-inhibitors? An observational study from the Nordic countries.

When used according to clinical practice in the Nordic countries, the observed first-year absolute risk of hospitalized infection was doubled for secukinumab compared with adalimumab. This excess risk seemed largely explained by confounding by indication.